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Background. Erythrocytes represent an important compo-
nent of the antioxidant capacity of blood, comprising, in partic-
ular, intracellular enzymes, including platelet-activating factor
acetylhydrolase (PAF-AH) and glutathione peroxidase (Gpx).
We evaluated the erythrocyte PAF-AH and Gpx activities in
various stages of chronic kidney disease (CKD), and further
investigated whether erythropoietin (EPO) administration in
these patients has any influence on the enzyme activities.
Methods. Thirty-six patients (19 men and 17 women) with
CKD (stages 1 to 5) participated in the study. Thirteen of them
presented with CKD stage 1 to 2 (group I), whereas 23 pa-
tients presented with CKD stage 3 to 5 and randomized into
two groups (i.e., groups II and III). Patients of group II (N = 11)
were administered EPO subcutaneously, 50 units per kg once
per week. In group III (N = 12), EPO was initiated only when
the hemoglobin (Hb) levels decreased during follow-up to less
than 9 g/dL. All patients were seen on an outpatient basis at
2 and 4 months. Fifteen normolipidemic age- and sex-matched
healthy volunteers also participated in the study and were used
as controls. The PAF-AH and Gpx activities were determined
in isolated washed erythrocytes.
Results. The erythrocyte-associated PAF-AH and Gpx activi-
ties were higher in all CKD patient groups at baseline compared
to controls, the groups II and III exhibiting significantly higher
enzyme activities compared with group I. In all studied popula-
tions, both enzyme activities were negatively correlated with the
creatinine clearance values. Importantly, the PAF-AH and Gpx
activities were progressively decreased during the follow-up in
patients not treated with EPO (group III), a phenomenon not
observed in patients receiving EPO (group II), or in patients
of group I. This reduction in enzyme activities was positively
correlated with the decrease in the creatinine clearance values
in patients of group III.
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Conclusion. Significant alterations in the erythrocyte-
associated PAF-AH and Gpx activities related to the disease
stage are observed in CKD patients. Administration of EPO
prevented the reduction in enzyme activities observed during
the progression of the renal insufficiency, thus preserving the
erythrocyte defense mechanisms against oxidative stress.
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-
sn-glycero-3-phosphocholine) is a proinflammatory
phospholipid mediator that is involved in several phys-
iopathologic conditions, and may have pivotal roles in
various syndromes or diseases, including renal diseases
[1, 2]. Studies in experimental animals and in humans in-
dicate that PAF may be an important mediator of renal
damage, suggesting that its production and action in the
kidney may be dysregulated in disease states [2].
Although several enzymes are involved in PAF
metabolism, a prominent role in the regulation of PAF ac-
tivity in vivo plays PAF-acetylhydrolase (PAF-AH) (EC
3.1.1.47), an enzyme that expresses a Ca2+-independent
phospholipase A2 activity and degrades PAF and oxi-
dized phospholipids by catalyzing the hydrolysis of the
ester bond at the sn-2 position [3]. Four intracellular (Ia,
Ib, II, and erythrocyte form) and one secreted (plasma
form) isoenzyme have been described. Among the in-
tracellular forms, the erythrocyte PAF-AH is a distinct
25-kD protein [4] that is found primarily in the cytosol,
whereas a small proportion of the total enzyme activ-
ity exists also in the membrane fraction [4]. In addition
to PAF, the erythrocyte PAF-AH hydrolyzes oxidatively
fragmented phospholipids, but it does not recognize as
substrates structural membrane nonoxidized phospho-
lipids [4]. By acting as a scavenger of oxidized phos-
pholipids, the erythrocyte PAF-AH may play important
roles in determining functional properties of these cells. It
has been suggested that it may prevent the enhancement
of lipid peroxidation and the formation of toxic com-
pounds, thus preventing the damage of cell membrane
and maintaining the membrane integrity of the cell [4].
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Furthermore, previous studies have shown that PAF-AH
may play an important role in maintaining the erythro-
cyte deformability [5, 6].
Increased oxidative stress is a feature characteristic of
patients with chronic kidney disease (CKD), as indicated
by the increase in various markers of oxidative stress
as well as by the reduction in antioxidant levels [7, 8].
Oxidative stress in CKD patients may contribute to mal-
nutrition, anemia, resistance to erythropoietin (EPO),
and to increased incidence of atherosclerosis and car-
diovascular disease [7, 9–11]. Anemia in CKD is mainly
treated with administration of EPO [12, 13], and a num-
ber of studies point out that EPO treatment slows the pro-
gression of renal disease [14, 15], and this phenomenon
can be attributed not only to the correction of anemia,
but also to the influence of inflammation and oxidative
stress in these patients [7].
Erythrocytes represent an important component of
the antioxidant capacity of blood, comprising, in par-
ticular, intracellular enzymes, including PAF-AH and
glutathione peroxidase (Gpx). Significant changes in the
erythrocyte antioxidant systems have been reported in
CKD patients [10, 16, 17], whereas EPO administration
seems to improve the erythrocyte antioxidant capacity [7,
18, 19]. To the best of our knowledge, there is a paucity of
data concerning the erythrocyte-associated PAF-AH ac-
tivity in CKD patients. By contrast, the plasma or serum
enzyme activity in CKD has been previously studied by
our group [20] and others [21], and these studies have pro-
vided contrasting results showing either that the plasma
enzyme activity is significantly higher [20] or it remains
unchanged [21] in CKD patients compared with controls.
We undertook the present study in order to evaluate pos-
sible alterations in the enzyme activity in various stages
of CKD and to investigate whether EPO administration
in these patients has any influence on the erythrocyte
PAF-AH.
METHODS
Study population
Thirty-six patients (19 men and 17 women, mean age
63 years, range 36–81 years) with CKD (stages 1 to 5)
participated in the study. Thirteen of them presented
with CKD stage 1 to 2 (blood hemoglobin, Hb, levels
14.5 ± 1.3 g/dL, hematocrit, Ht, values 39.5 ± 2.1%)
and categorized into patient group I. Twenty-three pa-
tients were presented with CKD stage 3 to 5 and exhib-
ited anemia (blood Hb levels 10.0 ± 0.6 g/dL, Ht values
31.00 ± 1.16%). All patients participated in this study
were randomly selected from a total population of 88
patients who participated in the recently published ran-
domized controlled trial [15]. Exclusion criteria were di-
abetic nephropathy, the presence of an easily correctable
cause of anemia such as iron deficiency (transferrin satu-
ration <20%), vitamin B12 and folate deficiency, transfu-
sion dependency, hemolysis, the presence of systemic dis-
eases, infections or inflammatory conditions that might
inhibit the effect of EPO [7, 9, 11], age <18 years or
>85 years, uncontrollable hypertension (blood pressure
<130/85 mm Hg), proteinuria >2 g per 24 hours, serum
albumin <3.5 g/dL, hepatic insufficiency, active hepatitis,
uncontrollable hypothyroidism, chronic alcoholism, con-
gestive heart failure (New York Heart Association class
III or IV), severe obesity (body mass index >40 kg/m2),
nPNA = <0.8 g/kg/day, history of seizures of thrombotic
episodes, pregnancy, lactation, known hypersensitivity to
EPO alpha, use of hypolipidemic drugs, use of corticos-
teroids in the previous 6 months, and use of EPO in the
previous 6 months. Because of concerns about induced
EPO resistance at the time the study was launched [7, 10,
11, 22–24], patients receiving angiotensin-converting en-
zyme inhibitors or angiotensin II receptor blockers could
participate if they were willing to stop these drugs and
adequate blood pressure control could be achieved with
other drugs for at least 2 months before proceeding with
randomization.
Patients of group I with CKD stage 1 to 2 were left
untreated, whereas patients with CKD stage 3 to 5 were
randomized into two groups (i.e., groups II and III). The
subjects of group II (N = 11) were administered EPO
(Eprex, Janssen-Cilag Pharmaceutical, Athens, Greece)
50 units per kg subcutaneously once per week. In group
III (N = 12), EPO was initiated only when the Hb levels
decreased during follow-up to less than 9 g/dL (confirmed
on a second measurement within less than 1 week). De-
tails of the protocol regarding visits during the following-
up, dose schedules, and titration of EPO are described in
our previous study [15].
Fifteen normolipidemic age- and sex-matched healthy
volunteers also participated in the study and were used
as controls. The clinical and laboratory characteristics of
the study population at baseline are shown in Table 1. All
study participants gave informed consent for the investi-
gation, which was approved by the Ethical Committee of
the University Hospital of Ioannina.
Preparation of cytosol and membranes of erythrocytes
Venous blood samples (12 mL) were collected after a
14-hour overnight fast in polystyrene vacuum tubes with
acid citrate as coagulant. Blood cells were sedimented
by centrifugation at 1500g for 20 minutes, and the super-
natant plasma, along with the buffy coat, was removed
by aspiration. The remaining erythrocyte pellet was then
washed 3 times with a 4.2 mmol/L HEPES buffer so-
lution, pH 7.4. A small portion of this suspension was
used for erythrocyte count. The remaining suspension
was centrifuged as above and the sedimented erythro-
cytes were lysed by mixing with 5 volumes of a 7 mmol/L
sodium phoshate buffer solution, pH 7.4, for 20 minutes
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Table 1. Clinical and laboratory characteristics of the study population
Controls Group I Group II Group III
Number 15 13 11 12
Age years 59 (32–79) 63 (37–76) 61 (36–81) 66 (45–79)
Females/males 12/10 5/8 5/6 7/5
Weight kg 69.2 ± 13.5 68.2 ± 10.3 72.3 ± 8.9 70.4 ± 9.4
History of hypertension, N (%) – 68 93 84
Hb g/dL 15.4 ± 1.3 14.5 ± 1.3 10.0 ± 0.6b,c 10.2 ± 0.4b,c
Ht% 40.6 ± 2.6 39.5 ± 2.1 30.8 ± 2.2b,c 31.2 ± 1.1b,c
Serum creatinine mg/dL 0.83 ± 0.12 1.00 ± 0.50 3.27 ± 0.99b,c 3.39 ± 0.82b,c
Creatinine clearance mL/min 109.0 ± 6.2 87.2 ± 7.1b 20.2 ± 6.5b,c 23.9 ± 6.6b,c
24-hour protein g nd 0.65 ± 0.39 0.66 ± 0.39 0.57 ± 0.36
Total cholesterol mg/dL 202 ± 33 206 ± 30 232 ± 33a 231 ± 37a
Triglycerides mg/dL 104 ± 55 150 ± 20a 149 ± 41a 153 ± 47a
LDL-cholesterol mg/dL 135 ± 32 139 ± 32 160 ± 33 156 ± 33
HDL-cholesterol mg/dL 46 ± 13 45 ± 15 42 ± 10 45 ± 10
Abbreviations are: Hb, hemoglobin concentration; Ht, hematocrit values; nd, not determined. Values represent the mean ± SD, except for age, which is expressed in
terms of median and range.
aP < 0.05 and bP < 0.001 vs. controls; cP < 0.001 vs. group I.
at 4◦C [25]. The erythrocyte lysate was then centrifuged
at 20,000g for 10 minutes at 4◦C to obtain the super-
natant (cytosol) and the sedimented erythrocyte mem-
branes. The membrane fraction was then washed up to 4
times with the 7 mmol/L sodium phoshate buffer solution,
until a colorless one was obtained. The membrane frac-
tion was suspended in 200 lL of the 4.2 mmol/L HEPES
buffer solution and stored along with the cytosolic frac-
tion at −80◦C.
Assay for PAF-acetylhydrolase activity
PAF-AH activity was measured by the trichloroacetic
acid precipitation procedure using 90 lL of the ery-
throcyte total lysate or the cytosol or the erythrocyte
membrane suspension, as the source of the enzyme, and
[3H]-PAF (100 lmol/L final concentration) as a substrate.
Incubations were performed for 10 minutes at 37◦C.
PAF-AH activity in both the cytosolic and membrane
fraction was expressed as nmol PAF degraded per min
per 109 cells or per g of Hb (total lysate or cytosolic
fraction).
Assay for glutathione peroxidase activity
Gpx activity was determined spectrophotometrically
as previously described [26], using a commercially avail-
able kit (Calbiochem, San Diego, CA, USA). Gpx activity
was quantitated by measuring the change in absorbance
at 340 nm caused by the oxidation of NADPH. One unit
(IU) is defined as the amount of enzyme that will cat-
alyze the oxidation of 1.0 mmol/L of NADPH to NADP
per minute at 37◦C, measured at 340 nm [26]. Fifteen lL
of the total lysate or the cytosol (diluted 1/10 v/v with
assay buffer) was used as the source of the enzyme. Gpx
activity was expressed as IU per minute per 109 cells or
per g of Hb.
Oxidation of intact erythrocytes in vitro
Washed erythrocytes were diluted with an equal vol-
ume of phosphate-buffered saline (PBS) buffer solution,
pH 7.4. Two mL of this suspension corresponding to
252 mg of Hb or 372 × 106 erythrocytes, was submitted to
oxidative stress in the presence of 0.2 mmol/L CuSO4 and
1 mmol/L ascorbic acid in a shaking water bath for 1 hour
at 37◦C. Oxidation was performed in the absence or in the
presence of EPO at various concentrations ranging from
1 to 8 IU/mL. The oxidation was terminated by addition
of 10 lL 10 mmol/L EDTA. The copper-ascorbate treated
erythrocytes were washed twice with PBS buffer solution,
pH 7.4. The packed cells were lysed with 2 volumes of
7 mmol/L sodium phoshate buffer (pH 8.0) at −4◦C for
20 minutes [25]. Lysates from untreated washed packed
erythrocytes were also prepared in a similar way and
served as the respective controls [27]. All lysates were
used for the determination of the Hb concentration, as
well as the activities of PAF-AH and Gpx.
Analytical methods
Products of lipid peroxidation were detected through
the measurement of thiobarbituric acid–reactive
substances (TBARS). TBARS were determined in
EDTA-anticoagulated plasma by using a spectropho-
tometric assay, essentially as previously described [28].
Serum total cholesterol, high-density lipoprotein (HDL)-
cholesterol, and triglyceride levels were determined
on the Olympus AU560 Clinical Chemistry analyzer
(Hamburg, Germany) as previously described [29].
Serum low-density lipoprotein (LDL)-cholesterol levels
were calculated using the Friedewald formula. Creatinine
and protein levels in serum and urine were measured by
the Jaffe´ and the biuret methods, respectively, whereas
albumin was determined by the bromocresol green
method.
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Table 2. Hb levels and Ht values in EPO-treated patients of group II and in untreated patients of group III
Group II Group III
Baseline 2 months 4 months Baseline 2 months 4 months
Hb(g/dL) 10.0 ± 0.6 11.7 ± 0.8b 12.2 ± 0.9b 10.2 ± 0.4 10.6 ± 0.5 10.4 ± 0.6
Ht (%) 30.8 ± 2.2 36.0 ± 2.4b 37.6 ± 2.7b 31.2 ± 1.1 31.6 ± 1.0 32.1 ± 1.5
MCV (fl) 81.1 ± 8.1 80.4 ± 7.8 81.1 ± 8.1 87.7 ± 2.7 87.4 ± 3.2 86.4 ± 2.3
MCH(pg) 26.3 ± 3.2 26.2 ± 3.2 26.2 ± 3.0 28.7 ± 1.4 28.7 ± 1.1 28.5 ± 1.3
MCHC(g/dL) 32.4 ± 1.2 32.5 ± 1.3 32.4 ± 1.0 32.8 ± 0.7 32.9 ± 0.9 33.0 ± 0.8
Creatinine clearance (mL/min) 20.2 ± 6.5 20.4 ± 7.2 19.2 ± 7.0 23.9 ± 6.6 22.8 ± 7.3 18.3 ± 5.3a
Abbreviations are: MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration Values represent the mean ± SD.
aP < 0.05 and bP < 0.001 vs. baseline values.
Statistical analysis
Values are expressed as mean ± SD, except for age,
which are expressed in terms of median and range. A
comparison of continuous variables was performed by
unpaired two-tailed t test, as well as by one-way analy-
sis of variance with multiple Scheffe-type comparisons.
The distribution of erythrocyte PAF-AH and Gpx ac-
tivities was tested for normality using the Kolmogorov-
Smirnov test. Because the enzyme activity values did not
significantly differ from normal distribution in all studied
groups, one-way analysis of variance (with Fisher least
significant difference method for multiple comparisons)
was used to compare enzyme activities among groups.
Correlations between enzyme activities and covariates
were estimated using Pearson’s correlation coefficients.
Pearson’s v 2 test was used to assess the difference in
prevalence between the studied groups. Significance lev-
els were set at 0.05 in all cases.
RESULTS
Characteristics of the study population
As shown in Table 1, no difference in the age, sex dis-
tribution, and weight values was observed among the
studied groups. Patients of group I exhibited significantly
lower creatinine clearance values at baseline compared
with controls, whereas no significant differences were ob-
served in the Hb and Ht values or in the lipid parameters
between these two groups. As expected, patient groups II
and III exhibited significantly lower Ht and Hb levels at
baseline compared either with controls or with patients
of group I. Baseline serum creatinine levels, as well as
total cholesterol, LDL-cholesterol, and triglyceride lev-
els were significantly higher in groups II and III, whereas
creatinine clearance levels were significantly lower com-
pared either to group I or to controls. As expected, the
Hb values were positively correlated with the creatinine
clearance values (r = 0.813, P < 0.001) in the whole stud-
ied population. Finally, no difference was observed in all
studied parameters between groups II and III.
Hematologic and biochemical parameters during
the follow-up
All patients were seen on an outpatient basis at 2 and
4 months. There were no significant changes compared
with the baseline values in the Hb and Ht levels in the
erythrocyte markers, MCV, MCH, and MCHC, as well as
in the creatinine clearance values in patients of group I, ei-
ther at 2 or at 4 months after the onset of the study (data
not shown). No significant changes were also observed
in all hematologic parameters in untreated patients of
group III, whereas the creatinine clearance values were
progressively reduced at 2 or at 4 months, reaching a sta-
tistical significance at 4 months from the onset of the study
(Table 2). EPO administration in patients of group II
caused a significant progressive increase in Hb and Ht
levels during the follow-up compared to the baseline val-
ues, whereas the creatinine clearance values remained
unaltered (Table 2). Finally, no significant changes in the
erythrocyte markers were observed in this patient group
during the follow-up (Table 2).
Erythrocyte PAF-acetylhydrolase activity
PAF-AH activity was determined in the erythrocyte
cytosolic and membrane fractions. As shown in Figure
1A, the enzyme activity in the erythrocyte cytosol of all
patient groups at baseline was significantly higher com-
pared to controls. Importantly, CKD stage 3 to 5 patient
groups (groups II and III) exhibited significantly higher
enzyme activity compared with group I. Similar results
were obtained when the enzyme activity was expressed
in nmol/g Hb/min (198 ± 45, 277 ± 29, 440 ± 90, and
430 ± 116 for controls, group I, group II, and group III,
respectively, P < 0.05 for comparisons between group I
and controls or groups II and III, P < 0.001 for compar-
isons between group II or III and controls). Similarly, the
PAF-AH activity associated with the membrane fraction
in all patient groups was significantly higher compared
with controls, group I having significantly lower enzyme
activity compared with either group II or group III
(Fig. 1B). In the control group, as well as in each pa-
tient group, the enzyme activity associated with the
membrane fraction comprises 0.83 ± 0.07% of the total
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Fig. 1. Baseline values of PAF-AH activity in the cytosolic (A) and
the membrane fractions (B) of erythrocytes from CKD patients and
controls. PAF-AH activity was determined by the TCA precipitation
method. Data are expressed as mean ± SD. ∗P < 0.05 compared with
controls; ∗∗P < 0.001 compared with controls; and $P < 0.05 compared
with group I.
activity in erythrocytes (the sum of cytosolic and
membrane-associated PAF-AH activity), and this obser-
vation is in accordance with previously published re-
sults [4, 30]. We should note that the PAF-AH activity
in the cytosol was negatively correlated with the creati-
nine clearance values in all studied population (Fig. 2).
Similarly, a negative correlation was observed between
the membrane-associated enzyme activity and creatinine
clearance values in all studied population, r = −0.799,
P < 0.001.
PAF-AH activity was also determined during the
follow-up, at 2 and 4 months. An important observation of
the present study is that in patients not treated with EPO
(group III), the PAF-AH activity in both the cytosolic and
membrane fractions was decreased during the follow-up
(Fig. 3A and B). Thus, at 4 months, the enzyme activity
was decreased by 33.6% in the cytosol and by 31.9% in the
membrane fraction compared to the respective baseline
values. Similar results were obtained when the enzyme ac-
tivity was expressed in nmol/g Hb/min (data not shown).
The reduction in PAF-AH activity was positively corre-
lated with the decrease in the creatinine clearance values
(Fig. 4). Unlike in untreated patients, the post-treatment
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Fig. 2. Correlation between the cytosolic PAF-AH activity and creati-
nine clearance values in all studied populations.
values of enzyme activity in patients receiving EPO were
not significantly changed during the follow-up (Fig. 3A
and B). Finally, the activity of PAF-AH in the cytosolic
and membrane fractions of patients of group I remained
unaltered during the follow-up (data not shown).
Erythrocyte glutathione peroxidase activity
The baseline values of the Gpx activity in the total cell
lysate were significantly higher in both patient groups
compared to controls, the group I patients presenting
significantly lower enzyme activity compared with either
group II or group III (Fig. 5A). Similar results were ob-
tained when the enzyme activity was expressed in IU/g
Hb (9.98 ± 3.33, 11.30 ± 2.88, 15.20 ± 4.70, and 15.50 ±
5.00 for controls, group I, group II, and group III, re-
spectively). In all studied groups, the Gpx activity was
negatively correlated with the creatinine clearance val-
ues, r = −0.439, P < 0.05. During the follow-up, the Gpx
activity was progressively decreased at 2 and 4 months in
untreated patients of group III, whereas it did not signifi-
cantly change in patients of group II (Fig. 5B). The reduc-
tion in Gpx activity in group III was positively correlated
with the decrease in the creatinine clearance values, r =
0.751, P < 0.05.
Plasma TBARS levels
To investigate whether there is any role of oxidative
stress in the alterations described above of the erythro-
cyte PAF-AH and Gpx activities, we determined the con-
centration of TBARS in plasma as an indicator of free
radical-induced lipid peroxidation. TBARS levels were
determined in all studied groups and expressed as nmol of
malondialdehyde (MDA) equivalents/mL of plasma. Pa-
tients of group I exhibited higher TBARS levels at base-
line compared with controls; however, these did not reach
statistical significance. By contrast, patients of groups II
and III exhibited significantly increased baseline plasma
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Fig. 3. Erythrocyte-associated PAF-AH activity in CKD patients of
stages 3 to 5 at baseline and during the follow-up. (A) Cytosolic fraction.
(B) Membrane fraction. PAF-AH activity was determined by the TCA
precipitation method. Data are expressed as mean ± SD. ∗P < 0.05 and
∗∗P < 0.005 compared with baseline values.
TBARS levels compared either to controls or to patients
of group I (Fig. 6A). Finally, no significant differences
were observed during the follow-up in patients of either
group II or group III (Fig. 6B).
Effect of erythrocyte oxidation on PAF-AH and GPX
activities in vitro
To further investigate whether oxidative stress plays
any role in the alterations described above of the
erythrocyte-associated enzyme activities, as well as the
possible effect of EPO, we performed experiments in
vitro in which we studied the effect of erythrocyte oxi-
dation on the PAF-AH and Gpx activites in the absence
or in the presence of EPO. Erythrocytes from all studied
groups, prepared at baseline, were submitted to oxidation
in vitro, as described in Methods. Erythrocyte oxidation
resulted in the cell lysis, which was determined as an in-
crease in Hb concentration in the supernatant after the
cell sedimentation. No difference in the Hb concentration
in the supernatant of erythrocytes after oxidation was ob-
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Fig. 5. Erythrocyte-associated Gpx activity (A) in all study populations
at baseline and (B) in CKD patients of stages 3 to 5 at baseline and
during the follow-up. Gpx activity was determined spectrophotometri-
cally and quantitated by measuring the change in absorbance at 340 nm
caused by the oxidation of NADPH. One IU is defined as the amount
of enzyme that will cause the oxidation of 1.0 mmol/L of NADPH to
NADP per minute at 37◦C measured at 340 nm Data are expressed as
mean ± SD. ∗P < 0.05 and ∗∗P < 0.001 compared with controls. $P <
0.05 compared with baseline values of group III.
served among the studied groups (data not shown). In
addition to hemolysis, oxidation of erythrocytes from all
studied groups leads to a significant decrease in the PAF-
AH and Gpx activities, measured in the total lysate, which
was similar in all studied groups. Figure 7A and B demon-
strates the results from the oxidation experiments using
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Fig. 6. Plasma TBARS levels (A) in all study populations at baseline
and (B) in CKD patients of stages 3 to 5 at baseline and during the
follow-up. TBARS levels in plasma were determined spectrophoto-
metrically, and expressed as nmol of malondialdehyde (MDA) equiv-
alents/mL of plasma. Data are expressed as mean ± SD. ∗P < 0.05
compared with either controls or group I.
erythrocytes from the control group. It should be noted
that the decrease in both enzyme activities could not be
attributed in enzyme loss due to hemolysis because both
enzyme activities were expressed per g of Hb. Addition
of EPO before the initiation of the erythrocyte oxidation
at various concentrations ranging from 1 to 8 IU/mL did
not prevent either the hemolysis or the reduction in both
enzyme activities. Figure 7A and B demonstrates the lack
of any effect of 2 IU/mL of EPO on the oxidation param-
eters of erythrocytes from the control group.
DISCUSSION
The results of the present study show for the first time
that the erythrocyte-associated PAF-AH activity in pa-
tients with CKD is progressively increased as a function
of the disease stage, the patients in stages 3 to 5 having
significantly higher enzyme activity compared to those
of stage 1 to 2. Furthermore, a negative correlation be-
tween the enzyme activity and the degree of renal insuf-
ficiency (expressed as creatinine clearance values) was
observed, suggesting a close relationship between the
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Fig. 7. Effects of Cu2+-induced oxidation of erythrocytes in the pres-
ence or absence of EPO in vitro. (A) Oxidation-induced erythrocyte ly-
sis and (B) oxidation-induced reduction in PAF-AH and Gpx activities.
Oxidation of washed erythrocytes was performed using the combina-
tion of 0.2 mmol/L CuSO4 and 1mmol/L ascorbic acid in the presence
or in the absence of 2 IU/mL EPO. Data are expressed as mean from 4
different erythrocyte preparations from the control population.
above-mentioned enzyme alterations and renal insuffi-
ciency. However, in CKD patients (stages 3 to 5), a pro-
gressive decrease in the enzyme activity is observed in
parallel to the progress of renal insufficiency, which is sig-
nificantly attenuated by EPO treatment. Similar results
were obtained for the erythrocyte-associated Gpx activ-
ity, and these are in accordance to previously published
data for the erythrocyte antioxidant systems [16]
It has been suggested that the erythrocyte PAF-AH is
important for the cell physiology because it protects the
cell against oxidation-induced damage by degrading the
toxic products of phospholipid peroxidation without act-
ing on structural membrane nonoxidized phospholipids
[4]. Such cytotoxic phospholipids can be generated dur-
ing erythrocyte peroxidation, and are capable of dam-
aging the erythrocyte membranes [31–33]. Furthermore,
the hydrolysis of oxidized phospholipids by PAF-AH al-
lows the subsequent restoration of membrane integrity by
reacylation of the lyso derivatives with long chain fatty
acyl groups [34, 35]. It is known that damage of erythro-
cyte membranes by lipid peroxidation leads to deterio-
ration of the rheologic properties of these cells [36], a
phenomenon that is observed in CKD patients and may
contribute to the reduced erythrocyte survival observed
in these patients [37]. Thus, by acting as a scavenger of ox-
idized phospholipids, the erythrocyte PAF-AH may con-
tribute in maintaining the membrane integrity and the
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erythrocyte deformability. This is also supported by pre-
viously published results showing that the erythrocyte
PAF-AH activity is positively correlated with erythro-
cyte deformability indices in stroke patients [5]. Oxidized
phospholipids formed on the membrane of erythrocytes
may also represent a signal for the cell recognition by
scavenger receptors of macrophages, primarily the CD36,
thus leading to their subsequent elimination from the cir-
culation and to a decrease in their life span in blood
[33, 38]. In this context, it has been demonstrated that
in chronic uremia the percentage of annexin V-positive
erythrocytes (annexin V recognizes phosphatidylserine
molecules as well as oxidized phospholipids) increases
with the progressive decline in renal function, and may
contribute to the reduced erythrocyte life span and to
the anemia that characterizes these patients [39]. Con-
sequently, PAF-AH could be an important enzyme for
erythrocytes, which may work in concert with the well-
known intracellular antioxidant systems to protect them
from oxidative damage, to conserve the cell functionality,
and to prolong their life span in blood, which is reduced in
CKD. Overall, we may suggest that the augmentation of
erythrocyte PAF-AH observed at baseline in all groups
of our CKD patients represents an adaptive mechanism
of these cells to the increased oxidative stress, which has
been previously shown to occur in CKD patients [40].
The increased oxidative stress in CKD patients is also
supported by the results of the present study showing
a significant elevation of TBARS in the plasma of pa-
tients with CKD stage 3 to 5. Because erythrocytes are
anucleate cells and contain only preformed proteins, the
enhancement in PAF-AH and Gpx activities could be at-
tributed to exposure of the erythropoietic stem cells to
increased oxidative stress with a consequent adaptive re-
sponse. Despite the increase in the erythrocyte PAF-AH
activity, and the important role that it may play for ery-
throcyte deformability and life span in CKD, it did not
prevent the anemia observed in our patients of groups
II and III, thus suggesting that the low rate of the ery-
throcyte production, rather than the decrease in the cell
life span in blood, could be the major determinant of the
anemia observed in CKD.
An important observation of the present study is that
during the follow-up of patients with CKD stage 3 to 5
who were not treated with EPO, the erythrocyte PAF-AH
activity was significantly decreased, and this reduction
was positively correlated with the progression of renal in-
sufficiency (decrease in creatinine clearance values). Sim-
ilar results were obtained for the Gpx activity. Based on
this data we may suggest that there is a critical point dur-
ing the disease progression in which the erythropoietic
stem cells of predialysis CKD patients lose their adap-
tive mechanisms, which were responsible for the increase
in the erythrocyte PAF-AH and Gpx activities. Consis-
tent with this hypothesis are the previously reported re-
sults showing that CKD patients before hemodialysis, or
CKD patients receiving either hemodialysis or continu-
ous ambulatory peritoneal dialysis, exhibit lower erythro-
cyte SOD and Gpx activities, as well as glutathione levels
[16, 17, 41, 42].
We should emphasize that the above-mentioned re-
duction in PAF-AH and Gpx activities was not observed
in patients treated with EPO, neither of these patients
exhibited a further decrease in creatinine clearance val-
ues. According to our recently published results, EPO
administration in these patients significantly slows the
progression of renal insufficiency, and delays the initia-
tion of renal replacement therapy [15]. Thus, based on the
important role that the erythrocyte PAF-AH may have
for the cell functionality and life span in CKD, we may
suggest that the EPO-induced inhibition of the progres-
sive inactivation of the erythrocyte PAF-AH could signifi-
cantly contribute to the retardation of the progression of
renal insufficiency observed in CKD patients receiving
EPO [15].
To investigate whether the reduction in erythrocyte
PAF-AH during the follow-up was due to any effect that
oxidative stress may have on the enzyme activity, we
submitted erythrocytes to oxidation in vitro. Under our
experimental conditions, oxidation induced a significant
decrease in the PAF-AH activity, and this finding is in
accordance with previously published results suggesting
that this enzyme is sensitive to oxidation [4]. EPO at any
concentration used did not prevent the oxidation-induced
reduction in the enzyme activity in vitro. Based on the
above results, the decrease in enzyme activity observed
in CKD patients could be attributed to the erythrocyte ex-
posure in an increased oxidative stress. However, accord-
ing to our results, the plasma TBARS concentration did
not increase either at 2 months or at 4 months of follow-
up; thus, this hypothesis is unlikely. Furthermore, the pre-
vention of the enzymatic activity reduction by EPO could
not be attributed to any antioxidant effect of this hor-
mone because neither had it protected the enzyme from
the oxidation-induced inactivation in vitro, nor had it re-
duced the plasma levels of TBARS during the follow-up.
It has been reported that the erythrocyte PAF-AH activ-
ity is reduced as erythrocyte density is increased (i.e., with
in vivo aging of these cells). This may be due to enzyme
consumption induced by a mechanical stress of repeated
change in cell shape, or by its release with vesicles through
microvesiculation [43, 44]. Thus, we may hypothesize that
the EPO-induced prevention of the PAF-AH inactivation
could be due to the hormone-induced production of new
erythrocytes, thus resulting in the increase of the number
of young cells in the circulation, a phenomenon that does
not occur in patients not treated with EPO. The same phe-
nomenon may occur for the Gpx, which is not decreased
in our EPO-treated patients, since previous studies have
demonstrated that young erythrocytes contain increased
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levels of catalase, Gpx, and glutathione reductase activi-
ties [35, 43–45].
CONCLUSION
CKD patients exhibit significant alterations in the
erythrocyte-associated PAF-AH activity that are related
to the disease stage and to the progression of the renal
insufficiency, and may represent a defensive mechanism
against the erythrocyte deformability and decreased life
span in blood observed in these patients. Administration
of EPO prevented the decrease in the erythrocyte PAF-
AH activity observed during the progression of the renal
insufficiency; thus, it preserves the erythrocyte protection
mechanisms against oxidative stress.
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